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Abstract 
Purpose: To investigate the anti-arthritic activity of the water extract of Rhizoma Arisaematis (WERA) 
using a collagen II -induced arthritis (CIA) rat model. 
Methods: CIA was induced in male Sprague-Dawley rats by intradermal injection of bovine collagen II 
in Complete Freund’s Adjuvant. The rats were treated with daily oral doses of WERA (100, 200, and 
400 mg/kg) for 21 consecutive days. Methotrexate (MTX, 3 mg/kg), used as a positive control, was 
administered orally 2 times/week for 3 weeks. The severity of arthritis was evaluated using indices of 
paw swelling, arthritic score, body weight, thymus index, and spleen index. In addition, the serum levels 
of IL-1β, IL-6, IL-10, and TNF-α were measured. 
Results: All doses of WERA significantly inhibited paw edema (p < 0.01), decreased arthritis scores (p 
< 0.01) and spleen index (p < 0.05), and alleviated the weight loss associated with CIA in rats. 
Furthermore, TNF-α, IL-1β, and IL-6 serum levels were significantly decreased (p < 0.05) by all doses of 
WERA. By contrast, IL-10 serum levels were markedly increased (p < 0.05).  
Conclusion: WERA exerts therapeutic effects in CIA in rats by decreasing the serum levels of TNF-α, 
IL-1β, IL-6 and IL-10, suggesting WERA may be an effective candidate drug for treating human 
rheumatoid arthritis.  
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Rheumatoid arthritis (RA) is an autoimmune 
disease characterized by synovial inflammation 
and hyperplasia, cartilage and bone destruction, 
and chronic joint destruction with bone erosion in 
the extremities (especially the fingers) [1]. In 
addition, RA may also affect multiple organs and 
tissues, including the heart, lung, and nervous 
system. The average morbidity of RA is 1 % 
throughout the world, and the prevalence of RA 
is three times higher in females than in males [2]. 
This disease can rapidly progress into multi-
system inflammation with irreversible joint 
damage, causing premature mortality, disability 
and compromised quality of life in the 
industrialized and developing world [3,4]. 
Currently, the major categories of RA 
medications used in the clinical setting include 
disease-modifying anti-rheumatic drugs 
(DEMARDs), non-steroidal anti-inflammatory 
drugs (NSAIDs), steroid hormone and biologics 
(TNF-α antibody and the decoy TNF-α receptor) 
[5]. Long-term use of these drugs leads to 
immune system weakness, bone marrow 
suppression, liver and kidney impairment, 
gastrointestinal discomfort and cartilage 
degeneration [6]. Thus, additional effective drugs 
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with low toxicity are needed. In recent years, 
there have been an increasing number of reports 
that traditional Chinese medicines (TCMs) can 
serve as source of new, alternative drugs [7,8]. In 
addition, most RA patients are very likely to use 
plant-derived agents for treating RA [9,10]. 
These reports suggest that finding new RA drugs 
from commonly used TCMs may be a promising 
strategy. 
 
Rhizoma Arisaematis (RAM), the tuber of 
Arisaema erubescens (Wall.) Schott, has been 
used medicinally for more than two thousand 
years. As a folk remedy in China, RAM is 
primarily used to treat rheumatism, swelling, 
inflammation, and convulsions. In addition, RAM 
is commonly used as a key component in 
formulas for treating RA in Chinese folk 
medicines such as Lijie Capsule, Fufang Nanxing 
Zhitong Gao, and Aizheng Zhentong Powder [11-
14]. Previously published investigations indicated 
that the active components in RA include 
alkaloids, flavones, guanosines, polysaccharides, 
γ-aminobutyric acids, dipeptides, and steroids 
[15-18]. 
 
The aim of the present study was to investigate 
the anti-arthritic effect of the water extracts of 
RAM (WERA) and explore its potential 




Reagents and apparatus 
 
Bovine collagen type II (CII) and Complete 
Freund's Adjuvant (CFA) were purchased from 
Sigma Chemical Co. (Shanghai, China); 
Methotrexate (MTX) was purchased from 
Shanghai Sine Pharmaceutical Co., Ltd. 
(Shanghai, China). TNF-α, IL-1β, IL-6, and IL-10 
ELISA kits were purchased from the R&D system 
(Shanghai, China). All other chemicals and 
biochemicals used were of the highest grade 
available. 
 
The following instruments were used: Agilent 
1260 Series High Performance Liquid 
Chromatography-Diode Array Detector (HPLC-
DAD); Agilent Technologies, Inc., Folsom, (CA, 
USA); Plethysmometer PV-200 (ChengDu 
Technol & Market Co., Chengdu, China); FLx 
800 Fluorescence Microplate Reader (BioTek, 
Shanghai, China). 
 
Preparation of WERA 
 
RAM was purchased from Jiangyou Herbal 
Medicinal Materials Market (Sichuan Province, 
China) and identified by Prof. C.J. Wu, Chengdu 
University of Traditional Chinese Medicine 
(Chengdu, China). A voucher specimen 
(S20141015-01) was deposited in the College of 
Pharmacy of Chengdu University of Traditional 
Chinese Medicine. 
 
Sliced dried RAM tubers were extracted twice 
with hot water (each extraction was 2 h). The 
extracts were centrifuged at 5000 rpm for 20 min 
to remove starch. The supernatants were dried 
via a rotary evaporation method at 50 °C to 
obtain WERA. 
 
High-performance liquid chromatography 
(HPLC) analysis of WERA 
 
HPLC separation was performed on the Agilent 
1260 HPLC system with a C18 chromatographic 
column (250 × 4.6 mm, i.d. 5 μm), which was 
equipped with a quaternary pump, and an 
automatic thermostatic column compartment. 
Separation was performed using a gradient 
elution [H2O (A)/methanol (B)] at a flow rate of 
0.8 mL/min. Samples were analyzed using the 
following gradient program: the run was 
commenced with 5 % B and then a linear 
gradient to 10 % B within 6 min, followed by a 
linear gradient to 20 % B in 30 min that was 
maintained until 50 min, and finally a linear 
gradient to 30 % B in 60 min. The sample 
injection volume was 10 μL, the detection 
wavelength was set at 260 nm, and the column 
temperature was set at 30 ºC. 
 
Animals and grouping 
 
Male Sprague-Dawley rats (weighing 160 - 180 
g) and KM mice (weighing 18 - 22 g) were 
purchased from Chengdu Da-Shuo Lab Animal, 
LTD (Chengdu, China). Animals were kept in an 
environment with controlled temperature (24 - 26 
°C) and photoperiod (12:12 h light–dark cycle) 
and were given standard commercial rat chow 
and water. Following 1 week of acclimatization, 
10 animals were randomly assigned to each of 
six groups: the normal group (no treatment), the 
RA group (no exposure to WERA or MTX) , the 
MTX group (3 mg/kg, twice/week), the WERA 
low-dose group (100 mg/kg/d), the WERA 
middle-dose group (200 mg/kg/d) and the WERA 
high-dose group (400 mg/kg/d). Animal 
experiments were conducted in accordance with 
current ethical regulations for animal care and 
use at Chengdu University of Traditional Chinese 
Medicine. 
 
Acute toxicity of WERA 
 
An acute toxicity study of WERA was carried out 
using Organisation for Economic Co-operation 
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and Development (OECD) guidelines [19]. A 
series of doses of WERA (5, 50, 500, 2000, 
5000, and 10000 mg/kg animal body weight) was 
prepared by suspending WERA with 0.5 % (w/v) 
sodium carboxylmethyl cellulose (CMC-Na). 
Subsequently, the toxicity of WERA was 
evaluated following oral administration of the 
prepared series of WERA doses to KM mice. 
Mortality rates and abnormal behaviors of the 
mice were observed and recorded within 24 h. 
 
Collagen-induced arthritis (CIA) 
 
The CIA rat model was established according to 
methods described previously [20]. Bovine CII (2 
mg/mL in 0.05 M acetic acid) was emulsified with 
an equal volume of CFA to achieve a final 
concentration of 1 mg/mL. Rats were injected 
subcutaneously with the collagen emulsion (0.5 
mg/rat) at the tail root, hind-paw, and three 
places on the back (dorsonuchal, towards the tail 
about two-thirds of the way down the back, and 
towards the tail about one-third of the way down 
the back). After 1 week, a booster subcutaneous 
injection of the collagen emulsion (0.5 mg/rat) 
was administered at the same locations. From 
days 1 to 21 following the first injection, the 
WERA and MTX groups were treated orally with 
WERA and MTX, respectively, and the normal 
and RA groups were given an equal volumes of 
CMC-Na. 
 
Determination of arthritic score 
 
The severity of arthritis in CIA rats was assessed 
according to a previously described method [21, 
22]. Paws were examined and graded for 
severity and loci of erythema, swelling and 
induration using a 5-point scale (0 = no signs of 
disease, 1 = signs involving the ankle/wrist, 2 = 
signs involving the ankle plus tarsal of the hind 
paw and/or wrist plus carpals of the forepaw, 3 = 
signs extending to the metatarsals or 
metacarpals, and 4 = severe disease involving 
the entire hind or fore paw). The maximum 
arthritic score per rat was set at 16 (4 points × 4 
paws).  
 
Determination of thymus and spleen indices 
 
After 21 days of treatment, the rats were 
anesthetized with pentobarbital sodium (40 
mg/kg, intraperitoneal injection, i.p.) and 
sacrificed. The thymus and spleen were then 
promptly removed and weighed. The thymus and 
spleen indices were expressed as the ratio of the 
thymus or spleen wet weight (mg/g), 
respectively, divided by the body weight of the 
animal [23]. 
 
Determination of pro-inflammatory cytokines 
in serum 
 
Rat blood samples were obtained and allowed to 
clot for 1h at room temperature. Subsequently, 
serum was recovered and frozen at -20 °C prior 
to analysis [24]. The contents of TNF-α, IL-1β, IL-
6, and IL-10 in serum were determined by 





Data were presented as mean ±standard 
deviation and analyzed using SPSS 13.0 
statistical software (SPSS Inc., Chicago, IL, 
USA). Differences between groups were 
analyzed using one-way analysis of variance 





HPLC profile of WERA 
 
The three major constituents in the HPLC 
fingerprint of WERA were identified as inosine 
(retention time: 17.237 min), guanosine 
(retention time: 19.108 min) and adenosine 
(retention time: 37.762 min). The calculated 
contents of inosine, guanosine, and adenosine 
were 0.008, 0.051, and 0.042 mg/g, respectively 
(Figure 1). 
 
Acute toxicity of WERA 
 
In accordance with current OECD guidelines, 
WERA-treated animals were observed 
individually. Neither death nor any abnormal 
behaviors were observed during the toxicity 
study test period. The LD50 value could therefore 
not be calculated, indicating that oral 
administration of WERA at doses < 10 g/kg is 
safe. 
 
Effect of WERA on paw swelling, arthritis 
score, and body weight 
 
No obvious redness or joint swelling was 
observed in normal rats (Figures 2 and 3A). 
However, after CII injection, peripheral paw 
edema was observed in rats within 24 h. 
Furthermore, after 21 days of treatment by 
WERA (200 and 400 mg/kg) and MTX (3 mg/kg), 
paw edema was significantly decreased (p < 
0.01), compared with rats in the RA group 
(Figures 2 and 3C, E, F). 
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Figure 1: HPLC analysis of the water extract of Rhizoma Arisaematis (WERA). Peaks were detected at 260 nm, 
and 1-3 represented inosine, guanosine and adenosine, respectively 
 
 
Figure 2: Effect of WERA on paw edema of RA rats. Data are expressed as mean ± SD (n = 10); * p < 0.05, ** p 
< 0.01.  Normal;  RA;  MTX;  100 mg/kg;  200 mg/kg;  400 mg/kg 
 
 
Figure 3: Representative paws of rats photographed on day 21. A-F represent the rats in normal group, RA 
model group, WERA at 100 mg/kg, 200 mg/kg, 400 mg/kg, and MTX groups, respectively 
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Figure 4: Effect of WERA on arthritic scores of RA rats. Data are expressed as mean ± SD (n = 10). * p < 0.05, 




Figure 5: Effect of WERA on weight of RA rats. Data are expressed as mean ± SD (n = 10); * p < 0.05, ** p < 
0.01.  Normal;  RA;  MTX;  100 mg/kg;  200 mg/kg;  400 mg/kg 
 
Rat arthritis scores following 21 days of 
treatment with WERA (200 and 400 mg/kg) and 
MTX (3 mg/kg) were significantly decreased (p < 
0.05, p < 0.01, and p < 0.01, respectively) 
compared with those of RA rats following 13 
days of treatment (Figure 4). In addition, WERA 
(100 mg/kg) decreased arthritis scores from the 
13th to the 18th day of treatment, but these 
scores were not significantly different than those 
for RA rats on the 21st day of treatment. 
 
RA rats exhibited marked weight loss compared 
with normal rats by the 5th day of treatment (p < 
0.05; Figure 5). During the 2 weeks following the 
5th day of treatment, the weight loss of RA rats 
was reversed by administration of WERA at 
doses of 100, 200, and 400 mg/kg (p > 0.05). 
Although WERA-treated rats still showed less 
weight gain than normal rats, it was higher than 
the weight gain of MTX-treated rats. Overall, our 
results demonstrated that animals treated with 
WERA did not show significant weight loss 
during the experiment. 
 
Effects of WERA on thymus and spleen 
indices 
 
Both thymus and spleen indices in RA group 
were markedly increased compared with those in 
the normal group (p < 0.01; Figure 6). 
Interestingly, similar to MTX-treated (3 mg/kg) 
rats, the spleen indices of WERA-treated rats at 
doses of 100, 200, and 400 mg/kg were 
significantly decreased (p < 0.05) compared with 
those of RA rats. In addition, WERA at 400 
mg/kg significantly decrease the thymus index (p 
< 0.05) compared with that of RA rats. 
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Figure 6: Effects of WERA on the indices of thymus and spleen. Data are expressed as mean ± SD (n = 10). * p 
< 0.05, ** p < 0.01, compared to RA group 
 
Effects of WERA on serum levels of TNF-α, 
IL-1β, IL-6, and IL-10 
 
RA rats showed higher serum levels of TNF-α, 
IL-6, and IL-1β in RA rats (p < 0.01) but lower 
serum levels of IL-10 (p < 0.05) compared with 
normal rats (Figure 7). Similar to MTX treatment 
(3 mg/kg), WERA treatment (100, 200, and 400 
mg/kg) significantly decreased the serum levels 
of TNF-α (p < 0.05, p < 0.01, and p < 0.01 for the 
100, 200, and 400 mg/kg doses, respectively) 
and IL-6 (p < 0.01) compared with those in RA 
rats. In addition, WERA (200 and 400 mg/kg) 
significantly decreased the serum level of IL-1β 
(p < 0.01) and increased the IL-10 serum level (p 




Our investigation confirmed for the first time that 
WERA can alleviate the joint swelling and 
inflammatory symptoms of CII-induced RA rats. 
Our results also indicate that the mechanism of 
these effects might be a decrease in pro-
inflammatory cytokines, including TNF-α, IL-1β, 
and IL-6. 
 
The CIA animal model reproduces aspects of 
human RA, from genetic linkage to pathology 
and clinic manifestations, and is widely used to 
evaluate the therapeutic effects of candidate 
drugs and explore the pathogenesis and 
principles of therapy of RA [26]. Therefore, we 
used a CIA rat model to evaluate the anti-arthritic 
activity of WERA. Elimination of clinical 
symptoms of RA patients is a crucial index for 
evaluating the therapeutic effects of RA 
treatment [27], and arthritic scores and paw 
swelling are two commonly used indices for 
measurement of the anti-arthritic effects of drugs. 
Our results show that orally administered WERA 
significantly relieved joint swelling and redness in 
RA rats. In addition, treatment with WERA 
decreased swelling paw volume and arthritis 
scores and suppressed the weight loss of CII-
induced RA rats. 
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Figure 7: Effects of WERA on the releases of TNF-α, IL-1β, IL-6, and IL-10. Data are expressed as mean ± SD 
(n = 10). * p < 0.05, ** < 0.01, compared to RA group 
 
It has been reported that pro-inflammatory 
cytokines such as TNF-α, IL-1β, and IL-6 play 
crucial roles in the development of RA [28,29]. 
TNF-α has been considered to be on top of a 
cytokine cascade, which can increase the 
releases of IL-6 and IL-1β, and stimulate 
cartilage matrix degradation. In addition, IL-1β 
and IL-6 have been reported to contribute to the 
development of arthritis [30,31]. IL-10 plays a 
vitally important role in protecting the integrality 
of joint tissues and inhibiting releases of pro-
inflammatory cytokines in the pathological 
process of RA [32,33]. Interestingly, in our study, 
WERA significantly decreased the serum levels 
of TNF-α, IL-1β, and IL-6, whereas the level of 
IL-10 was markedly increased. Thus, the 
potential mechanism of the therapeutic effect of 
WERA on RA may involve both down-regulating 
of the level of TNF-α, IL-1β, and IL-6 and up-
regulating of the expression of IL-10. 
 
The thymus and spleen are the two major 
immune organs of body, and their relative 
weights are usually used to evaluate the 
immunoregulatory activity of drugs. After 
administration of WERA, RA rats exhibited a 
marked decrease of spleen and thymus indices. 
This result indicated that WERA might affect the 
immune function on RA rats. HPLC fingerprint 
analysis showed that the main components of 
WERA were nucleosides, which were previously 
found to be immunostimulatory agents [34]. 
Therefore, our results indicate that nucleosides 
may be responding active constituents for the 




The results of this study demonstrate that WERA 
is effective in treating CII-induced arthritis in rats 
via decreasing the spleen index, down-regulating 
TNF-α, IL-1β, and IL-6, and up-regulating L-10. 
Collectively, the results suggest that Rhizoma 
Arisaematis can potentially be developed for the 
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